Montrouge, France, May 12, 2022

DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting

Shareholders Approved All Proposed Resolutions

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. The General Meeting was chaired by Michel de Rosen, Chairman of DBV Technologies.

The Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors & Media section of the Company’s website:

About DBV TechnologiesDBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact Anne PollakDBV Technologies+1

Media ContactAngela MarcucciDBV Technologies+1 646-842-2393


  • PDF Version
DBV Technologies (EU:DBV)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more DBV Technologies Charts.
DBV Technologies (EU:DBV)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more DBV Technologies Charts.